Recently, it was reported that biomimetic cytomembrane nanovaccines could have long-term anti-tumor immunity and decrease regulatory T cells (Tregs), increasing the frequency of CD8+ T cells in the tumor and increasing spleen effector memory T cells. The gene discussed is CD8A; the disease is neoplasm.